

Supplementary Table 1. Participant characteristics

		Oncologists (N = 15)
Years in practice, mean (range)		18 (4–26)
Specialty, n (%)		
Medical oncology		12 (80.0)
Medical oncology + hematology oncology		3 (20.0)
Number of new patients in prior month, mean (range)		13 (2–50)
Location, n (%)		
Urban		6 (40.0)
Suburban		8 (53.3)
Rural		1 (6.7)
Clinical setting, n (%)		
Academic		5 (33.3)
Nonacademic		10 (66.7)
Region, n (%)		
Northeast		4 (26.7)
South		6 (40.0)
Midwest		3 (20.0)
West		2 (13.3)
Sex, n (%)		
Male		11 (73.3)
Female		4 (26.7)

Supplementary Table 2. Ranking of belief statements for ordering biomarker tests

Belief Statement	n^a	Frequency rank	Frequency score	Impact	Impact score	Conflict rank	Conflict score	Importance score
<i>I do/do not have complete knowledge of CLDN18.2 as a new actionable biomarker.</i>	12	H	3	H	2	H	2	7
Knowledge								
<i>I access credible knowledge sources to stay educated about biomarkers.</i>	12	H	3	H	2	L	1	6
Knowledge								
<i>Biomarker testing is/is not integrated into my EMR.</i>	14	H	3	H	2	H	2	7
Environmental context								
<i>I do/do not have the necessary support staff to help me with tasks related to biomarker testing.</i>	12	H	3	H	2	H	2	7
Environmental context								
<i>I do/do not feel that biomarker testing is urgent at the time of diagnosis.</i>	13	H	3	H	2	H	2	7
Motivation, goals, priorities								
<i>You're not doing your job if you don't order biomarker testing.</i>	11	H	3	H	2	L	1	6
Social/professional role								
<i>If I don't know biomarker test results, then I can't effectively treat the patient.</i>	14	H	3	H	2	L	1	6
Beliefs about consequences								

Frequency rank, H = 11–15; M = 6–10; L = 1–5; frequency score, H = 3; M = 2; L = 1; Impact on determining appropriate treatment, H/L; Impact score, H = 2; L = 1; Degree of conflicting beliefs, H/L; conflict score, H = 2; L = 1; importance score = total out of 7.

^aFrequency out of 15 respondents.

CLDN18.2, claudin 18 isoform 2; EMR, electronic medical record; H, high; L, low; M, medium.

Supplementary Table 3. Ranking of belief statements for determining appropriate treatment based on biomarker test results

Belief Statement Domain	n^a	Frequency rank	Frequency score	Impact	Impact score	Degree of conflicting beliefs	Conflict score	Importance score
<i>I do/do not have incomplete knowledge around PD-L1 status and how to use it to make treatment decisions.</i>	1	H	3	H	2	H	1	7
Knowledge								
<i>When PD-L1 and CLDN18.2 are both expressed, I vary my approach to treatment depending on the patient.</i>	8	M	2	H	2	H	2	6
Memory, attention, decision processes								
<i>I do/do not struggle to interpret biomarker test results.</i>	10	M	2	H	2	H	2	6
Skills								

Frequency rank, H = 11–15; M = 6–10; L = 1–5; frequency score, H = 3; M = 2; L = 1; Impact on determining appropriate treatment, H/L; Impact score, H = 2; L = 1; Degree of conflicting beliefs, H/L; conflict score, H = 2; L = 1; importance score = total out of 7.

^aFrequency out of 15 respondents.

CLDN18.2, claudin 18 isoform 2; H, high; L, low; M, medium; PD-L1, programmed death-ligand 1.